The KEYNOTE-522 Regimen Schedule for Breast Cancer

The KEYNOTE-522 regimen is a roughly year-long treatment plan for early-stage triple-negative breast cancer (TNBC) that combines the immunotherapy drug pembrolizumab with standard chemotherapy before surgery, then continues pembrolizumab alone after surgery. The schedule is divided into three distinct phases: two blocks of neoadjuvant (pre-surgery) therapy lasting about 24 weeks total, surgery itself, and then up to nine additional cycles of pembrolizumab as adjuvant (post-surgery) maintenance. The regimen became a standard of care after KEYNOTE-522, a large phase 3 trial, demonstrated that adding pembrolizumab to chemotherapy improved both the chances of eliminating the tumor before surgery and long-term survival.

Who the Regimen Is Designed For

KEYNOTE-522 was designed for patients with previously untreated, high-risk, early-stage TNBC. In the trial, eligible patients had stage II or stage III disease, meaning tumors that were either at least 2 centimeters in size or had spread to nearby lymph nodes, or both. Specifically, the criteria included tumors classified as T1c with positive lymph nodes (N1–N2) or T2–T4 regardless of nodal status (N0–N2). Patients needed to be at least 18 years old, have confirmed TNBC per standard pathology guidelines, and be well enough to tolerate intensive treatment.¹ Patients were not selected based on PD-L1 expression levels, which is notable because many other immunotherapy trials in breast cancer restrict enrollment to PD-L1-positive tumors.

The Neoadjuvant Phase, Step by Step

The pre-surgery portion of treatment runs for eight three-week cycles, split into two blocks of four cycles each. Understanding this schedule matters because the chemotherapy backbone changes halfway through, and the timing of each drug is specific.

During the first four cycles (roughly weeks 1 through 12), patients receive pembrolizumab at a flat dose of 200 mg intravenously every three weeks. Alongside it, they get two chemotherapy drugs: paclitaxel, given weekly at 80 mg/m², and carboplatin, given either weekly at a lower dose or every three weeks at a higher dose. The carboplatin schedule was left to the treating physician’s discretion in the trial, and patients were stratified by which carboplatin schedule they received.¹

During the second four cycles (roughly weeks 13 through 24), the chemotherapy switches to an anthracycline-based combination. Patients continue receiving pembrolizumab every three weeks, but paclitaxel and carboplatin are replaced by either doxorubicin (60 mg/m²) or epirubicin (90 mg/m²), combined with cyclophosphamide (600 mg/m²), all given every three weeks.² The choice between doxorubicin and epirubicin depends on institutional preference and the patient’s cardiac history, since both are effective but have slightly different side-effect profiles.

After completing all eight neoadjuvant cycles, patients proceed to definitive surgery, typically either a lumpectomy or mastectomy depending on how the tumor responded to treatment and the patient’s anatomy.

The Adjuvant Phase After Surgery

Following surgery, patients begin adjuvant pembrolizumab monotherapy at the same dose of 200 mg every three weeks, continuing for up to nine cycles. This phase lasts approximately 27 weeks if completed without interruption. In the trial, patients received pembrolizumab or placebo during this phase until they either completed all nine cycles, experienced disease recurrence, or developed side effects too severe to continue.¹ No chemotherapy is given in this phase under the standard KEYNOTE-522 protocol, though clinical practice has evolved to include additional agents for some patients, which is discussed below.

Altogether, the regimen spans roughly 15 months from the first infusion through the last adjuvant pembrolizumab cycle, not counting the weeks needed for surgery and recovery in the middle. In real-world practice, the vast majority of patients complete the neoadjuvant phase: one study of 174 patients found that 92% finished all eight planned pre-surgery cycles.³

Why This Particular Drug Sequence

The logic behind pairing chemotherapy with an immune checkpoint inhibitor like pembrolizumab goes beyond simply adding more drugs. Certain chemotherapy agents, particularly doxorubicin and related anthracyclines, can trigger a form of cancer cell death that activates the immune system. When cancer cells die this way, they release signals that attract immune cells, particularly dendritic cells, into the tumor. Those dendritic cells then present pieces of the dead tumor to T cells, priming them to hunt down remaining cancer cells.⁴

Pembrolizumab works by blocking PD-1, a protein on T cells that tumors exploit to shut down immune attacks. By combining a drug that activates immune recognition (the chemotherapy) with a drug that prevents the tumor from hiding from the immune system (pembrolizumab), the regimen creates a two-pronged assault. Preclinical research confirmed that combining anti-PD-1 therapy with immunogenic chemotherapy boosted CD8+ T-cell killing of cancer cells more effectively than either approach alone.⁵

Starting pembrolizumab alongside chemotherapy in the neoadjuvant setting, rather than saving it for after surgery, allows the immune system to begin mounting a response while the tumor is still present and actively shedding antigens. The continued post-surgery pembrolizumab then serves as maintenance, keeping the immune system vigilant against any remaining microscopic disease.

How Well the Regimen Works

The primary measure of the neoadjuvant phase’s success is pathological complete response, or pCR, the rate at which the tumor is entirely eliminated by the time of surgery. In KEYNOTE-522, about two-thirds of patients in the pembrolizumab group achieved pCR, compared with roughly half in the chemotherapy-only group. Pembrolizumab also appeared to improve pCR rates in traditionally harder-to-treat subgroups, including patients whose tumors were androgen-receptor positive or had low levels of immune cell infiltration.⁶

The longer-term results have been equally compelling. At three years, the estimated event-free survival was about 84.5% in the pembrolizumab group versus 76.8% with chemotherapy alone, translating to a 37% reduction in the risk of disease recurrence or death.⁷ At five years, the overall survival advantage held firm: an estimated 86.6% of patients in the pembrolizumab group were alive, compared with 81.7% in the chemotherapy-only group.⁸

An important nuance is that the benefit of adding pembrolizumab extended beyond just patients who achieved pCR. An exploratory analysis looking at residual cancer burden found that patients who had some residual disease after surgery (particularly those with a moderate amount) still benefited from having received pembrolizumab, with fewer recurrence events compared to the chemotherapy-only group.⁹ This finding suggests that pembrolizumab’s benefit is not solely explained by achieving complete tumor elimination. Something about the immune priming that occurs during neoadjuvant treatment appears to provide lasting protection even when some cancer cells survive.

Side Effects From the Immune Therapy Component

Chemotherapy-related side effects like nausea, fatigue, and hair loss are expected with this regimen and are similar to what patients would experience with the same chemotherapy drugs given without pembrolizumab. The added layer of concern comes from immune-related adverse events, or irAEs, which are side effects caused by the immune system becoming overactive and attacking healthy tissues.

How common these events are depends somewhat on the study. A large real-world study of 367 patients reported that about 31% experienced some form of immune-related side effect.¹⁰ A smaller single-institution study put the rate at about 28%, with hypothyroidism, rash, and arthritis being most frequent.¹¹ Another real-world cohort from Asia found a lower rate of about 14%, with hypothyroidism and adrenal insufficiency dominating.³ The variation likely reflects differences in how aggressively clinicians look for these events and how diverse the study populations are.

The most common immune-related side effects across studies include:

Thyroid problems: hypothyroidism is the single most frequent irAE, occurring in roughly 5–13% of patients depending on the study. It typically requires lifelong thyroid hormone replacement.
Skin reactions: rashes and itching affect around 7–8% of patients and are usually manageable with topical treatments.
Gastrointestinal issues: colitis and hepatitis together affect about 7% and are the most common cause of severe (grade 3 or higher) immune-related events.
Adrenal insufficiency: less common overall but can be serious, requiring ongoing steroid replacement. One real-world study reported a 4% rate.
Lung inflammation: pneumonitis is rare (around 1–4%) but potentially dangerous and requires prompt treatment.

Most immune-related side effects emerge during the neoadjuvant phase rather than the adjuvant phase. In the large real-world study, about 73% of irAEs appeared during neoadjuvant treatment, with only 28% occurring after surgery during the pembrolizumab maintenance phase.¹⁰

Managing Side Effects and Treatment Discontinuation

When immune-related side effects do arise, about 56% of affected patients need corticosteroids to bring the immune reaction under control. More aggressive immunosuppression is rarely needed: in one large cohort, only two patients required infliximab. However, pembrolizumab had to be permanently discontinued in roughly half of the patients who developed irAEs, which amounted to about 16% of all patients who received the drug.¹⁰ That is a substantial dropout rate, and it raises questions about whether patients who stop pembrolizumab early still benefit from the cycles they already received. The evidence from residual cancer burden analyses suggests the neoadjuvant immune priming carries lasting value, which is somewhat reassuring.

Hematologic toxicity from the chemotherapy component also deserves attention. Severe neutropenia (dangerously low white blood cell counts) is common, affecting over 40% of patients, and febrile neutropenia requiring hospitalization occurs in roughly 13%.³ Growth factor support (drugs that boost white blood cell production) is standard practice during the chemotherapy cycles to reduce this risk.

What Happens After Surgery if Tumor Remains

Not all patients achieve complete tumor elimination before surgery, and what comes next for those with residual disease is one of the most actively debated areas in TNBC treatment. The standard KEYNOTE-522 protocol has these patients continue adjuvant pembrolizumab alone, but in practice, many oncologists are adding additional agents.

Capecitabine, an oral chemotherapy, has established benefit in TNBC patients with residual disease after neoadjuvant treatment, showing improved recurrence-free survival, distant relapse-free survival, and overall survival compared to no adjuvant therapy.¹² However, the evidence for adding capecitabine to pembrolizumab specifically comes from the era before immunotherapy was standard. Expert opinion suggests the combination appears safe and can be considered, though definitive evidence from randomized trials is lacking.¹³

For patients with BRCA gene mutations who have residual disease, the PARP inhibitor olaparib is another option that may be combined with or sequenced after pembrolizumab. However, combining multiple agents simultaneously creates practical challenges. A study comparing concurrent versus sequential administration of these additional adjuvant drugs found that giving them at the same time as pembrolizumab led to higher toxicity rates, more dose adjustments, and more treatment discontinuations than giving them after pembrolizumab was finished.¹⁴ The sample sizes were small, so no definitive conclusions can be drawn, but the trend suggests that sequencing may be the more tolerable approach.

Ongoing clinical trials, including the OptimICE-pCR trial, are working to clarify whether patients who do achieve complete pathologic response truly need the full nine cycles of adjuvant pembrolizumab, or whether some can safely be spared the extra treatment.¹⁵

Surgical Complications Are Not Increased

A reasonable concern with adding immunotherapy before surgery is whether the activated immune system might cause more complications during healing. The evidence so far is reassuring. In a study comparing 139 patients treated with the KEYNOTE-522 regimen to 287 patients treated with chemotherapy alone, postoperative complication rates were similar: about 8% in the immunotherapy group versus 9% in the chemotherapy-only group. Immune-related side effects that occurred during neoadjuvant treatment were not associated with increased surgical complications.¹⁶

One pattern that has emerged, though, is that the timing between the last treatment dose and surgery matters. A study of 254 patients who underwent oncoplastic (more complex reconstructive) surgery found that complications were more frequent when surgery occurred either fewer than 14 days or more than 30 days after the final treatment dose. This timing effect was particularly pronounced in patients who had received pembrolizumab, suggesting there may be a sweet spot for scheduling surgery.¹⁷ Delayed wound healing was also somewhat more common in the immunotherapy group in that study, occurring in 10% versus about 4% of chemotherapy-only patients, though after adjusting for other variables, immunotherapy itself was not an independent risk factor for complications overall.

Quality of Life During and After Treatment

One of the more encouraging findings from KEYNOTE-522 is that adding pembrolizumab did not meaningfully worsen patients’ reported quality of life compared to chemotherapy alone. Patient-reported outcomes collected throughout both the neoadjuvant and adjuvant phases showed that overall health status, emotional functioning, physical functioning, and breast cancer-specific symptoms were comparable between the two groups. The differences were small enough to be clinically insignificant across all measured domains.¹ This is important because patients are already enduring a heavy chemotherapy regimen, and knowing that the immunotherapy addition does not pile on a substantially worse experience can influence treatment decisions.

That said, the quality-of-life data captures group averages. Individual patients who develop persistent thyroid problems, adrenal insufficiency, or other endocrine irAEs may face ongoing impacts that are not fully reflected in aggregate scores. Permanent endocrine damage, even when well managed with replacement hormones, represents a real long-term consequence of the regimen.

Fertility Implications for Younger Patients

TNBC disproportionately affects younger women compared to other breast cancer subtypes, making fertility preservation a pressing concern. A study specifically examining ovarian function in young TNBC patients found that adding pembrolizumab to chemotherapy did not appear to cause additional damage beyond what chemotherapy alone inflicts. One year after starting treatment, a key marker of ovarian reserve dropped dramatically in both groups, and the rates of undetectable ovarian reserve were statistically similar: about 53% in the pembrolizumab group versus 34% in the chemotherapy-only group, a difference that did not reach statistical significance. Hormone levels were also comparable between the two groups before and after treatment.¹⁸

The takeaway is that the chemotherapy backbone is the main driver of ovarian damage, not the pembrolizumab. Fertility preservation strategies such as egg or embryo freezing should be discussed before treatment begins, as they are with any young patient facing anthracycline-and-alkylating-agent-based chemotherapy. The immunotherapy component does not appear to add urgency to that conversation beyond what already exists.

Cost-Effectiveness Across Different Health Systems

Pembrolizumab is expensive, and the KEYNOTE-522 regimen adds roughly a year of immunotherapy on top of standard chemotherapy costs. Multiple health-economic analyses have evaluated whether the survival gains justify the added expense. In the United States, a modeling study estimated the regimen added about $79,000 in incremental costs but gained roughly 2.9 quality-adjusted life years, producing a cost per quality-adjusted life year of approximately $27,000, well below standard willingness-to-pay thresholds.¹⁹

The cost-effectiveness picture looks different in other health-care systems. In Switzerland, the incremental cost per quality-adjusted life year was estimated at about 14,100 Swiss francs, far below the national threshold, with a nearly 99% probability of being cost-effective.²⁰ In Egypt, the analysis similarly found the regimen cost-effective under national thresholds, though the absolute costs and thresholds were different.²¹ Across all three analyses, the large survival gains observed in KEYNOTE-522 drove the favorable economics. If the adjuvant phase could be safely shortened for good responders, the cost-effectiveness would improve further, which is part of the motivation behind de-escalation trials currently underway.